473734-19-9 Usage
Uses
Used in Pharmaceutical Industry:
4-(3-amino-2-hydroxybenzoyl)-N,N-dimethylpiperazine-1-carboxamide is used as a potential pharmaceutical compound for its structural features, including the presence of an amino group and a hydroxybenzoyl group. These functional groups may contribute to its potential therapeutic effects and interactions with biological targets.
The specific applications and reasons for its use in the pharmaceutical industry are not provided in the materials. However, given the structural features of the compound, it may be explored for various therapeutic areas, such as:
1. As a precursor in the synthesis of other pharmaceutical compounds.
2. As a modulator of biological pathways or receptors, depending on its binding affinity and selectivity.
3. As a prodrug that can be metabolized in the body to release an active pharmaceutical agent.
Further research and development would be required to determine the exact applications and therapeutic potential of 4-(3-amino-2-hydroxybenzoyl)-N,N-dimethylpiperazine-1-carboxamide in the pharmaceutical industry.
Check Digit Verification of cas no
The CAS Registry Mumber 473734-19-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,7,3,7,3 and 4 respectively; the second part has 2 digits, 1 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 473734-19:
(8*4)+(7*7)+(6*3)+(5*7)+(4*3)+(3*4)+(2*1)+(1*9)=169
169 % 10 = 9
So 473734-19-9 is a valid CAS Registry Number.
473734-19-9Relevant articles and documents
THIADIAZOLEDIOXIDES AND THIADIAZOLEOXIDES AS CXC- AND CC-CHEMOKINE RECEPTOR LIGANDS
-
Page 307, (2008/06/13)
Disclosed are novel compounds of the formula (IA) and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, acute pain, acute and chronic inflammatory pain, and neuropathic pain using a compound of formula (IA).
3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
-
Page 167; 168, (2008/06/13)
There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.
3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
-
Page 168, (2008/06/13)
There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.
